Every year we cook up an Inside Story feature that serves up the tasty morsels from our annual GSC Health Study. So readers, it’s time to feast…
But before we get all serious, shout-outs to the terrific audiences that gathered across the country between March and June. We would never be so bold as to claim they saw the best Health Study presentation ever, but we can report as a fact they saw the LONGEST. Clocking in at just over an hour, audiences endured a relentless onslaught of claims data, health research, and an unabashed opinion about the state of private health benefits plans in Canada. All survived, but the late afternoon start times and free-flowing adult beverages provided much-needed sustenance to survive our stress-inducing story.
What was that overarching story in 2017?
It was that all of us responsible for designing, administering, and writing the cheques for health benefits plans need to embrace data, research, and facts. We mean real facts, not the alternative variety that seem to be floating around south of the border. With this disciplined approach, we may be able to make difficult but necessary choices on coverage. This will be required to ensure our plans will be able to survive drugs that are priced in the tens of thousands, hundreds of thousands, or millions of dollars combined with a growing number of plan members and dependents spending up to their plan maximums on non-pharmaceutical benefits, namely health services, many with little or no research demonstrating their effectiveness.
We know these topics are not new to these pages or GSC Health Studies, but we did stir up some new topics to demonstrate the particular challenges we all face and provide a recipe for optimism—if we adopt some seemingly
LET'S GET STARTED
No recap of our Health Study can go far without reviewing the bottom-line numbers
on drug costs. The big money number we highlight each study is the year-over-year
increase in GSC’s total drug spend. This year that number was 5.8% over the study period.
Is that the sound of a relief-filled exhale you hear? Well, 5.8% is definitely better than last
year’s 9%. But let’s not set our bar so low. The last three years have seen successive
increases of 5%, then 9% on top of that 5%, now 5.8% on top of that gaudy number nine.
Not a terrific trend at all.
Just like last year, we also focused on the top one per cent of drug plan users, who made up 28.8% of overall drug costs and whose costs have been rising at four times the rate of the other 99% of drug plan users over the past five years. For the first time, our five percenters cracked the 50% mark of total GSC drug spend, at 50.2%, and we calculated that they have
been growing at three times the pace of the other 95% over the last five years.
High cost drugs… high cost claimants… a familiar refrain.
So we started looking for some dollars that could bring some relief.
IT'S THE BIOSIMILARS, STUPID
To paraphrase the infamous Clinton electoral strategy catchphrase from the late 80s, here’s one obvious topic in the world of high-cost drugs that takes us to the savings we need. There are literally hundreds of millions of dollars up for grabs for private and public drug plans if we get on the biosimilar bandwagon. But we’re kind of blowing it, especially in the private payor
world. Most carriers have been signing up for the easy deals—i.e., product listing agreements—to prop up the originator biologics, while uptake of equally effective, but materially less expensive biosimilars, is frustratingly low… except for those few of us that have developed
administrative policies requiring new patients to use them. At 7% market share, GSC generated 37% of Inflectra (the biosimilar for Remicade) claims in the private market. We’re hoping to see more of our friends in the industry join us to support building a viable biosimilar market in Canada through forward-looking strategies. We did it for generics last decade, so we can do it again.
Hands up, who is ‘Changing4Life’?
A hard nut to crack is getting our well-ingrained unhealthy habits to take a backseat to new healthy ones. There are lots of dollars to be had in getting us all healthier. Our data has clearly shown the cluster of chronic diseases that create our “Impactables” class of plan members—folks who combine a number of drug therapies to become one of those expensive five percenters noted earlier. What drugs? The ones that treat cholesterol, hypertension, diabetes… then mix in antidepressants, and lots of pain medication too.
The reduction in the human and financial cost of chronic disease was clearly at the heart of the creation of our online health management portal, Change4Life®. A year and a half after our launch, we have tens of thousands of users—and their fresh health risk assessment (HRA) data to sift through. For the first time ever, we gave audiences a peek at that data and asked:
who exactly is using the portal and what are they telling us about their health?
Who are the users? Well, mostly it is, duh… WOMEN! Two-thirds of users are women to be exact. Sorry, but we can’t resist tweaking those of you who are of the male persuasion by pointing out that this is not new news. Our Health Study data over the years has repeatedly shown that in adherence to prescription drug therapy, use of basic dental services… you
name it… men are the laggards.
The profile of the most-average Change4Life user is a middle-aged woman, heavier than a healthy weight, eating poorly, suffering from financial stress, but still trying to fit in some exercise!
Oh yes, she uses lots of massage too—and we know this because we specifically cross-referenced our claims data with the HRA data. In a first for a GSC Inside Story feature article, we will be brief on that topic. But you know what we’re thinking… a long brisk walk might often be a better, less expensive prescription for long-term health than a massage.
Bad medicine… is what we don’t need…
(Speaking of middle-aged, that is our first ever Jon Bon Jovi reference. 80s hearts are aflutter.)
The Health Study again shone a light on the tendency of our medical system to call too many of life’s inevitable ups and downs “depression,” with the go-to remedy being antidepressants as a first-line therapy. As a result, Canadians are the third-highest users of antidepressants in the world. Unsurprisingly, the perennial number-one drug-cost category at GSC is antidepressants—$45 million over the study period. Here’s the thing. Our mining of data, especially on adherence, leads us to believe that a sizeable portion of that money is spent on ineffective treatment for plan members that in turn becomes a wasted spend for plan sponsors. The preponderance of evidence tells us a lot of those plan members would be better served with mental health services—cognitive behavioural therapy (CBT) to be specific—in their community and/or online. Sure, that would also cost plan dollars, but we believe CBT would deliver better health outcomes for many plan members (you know, as in a value-based benefits spend for plan sponsors… GSC’s emerging obsession).
The big picture
Our call to action for Health Study attendees was to consider some of the hard decisions that loom over our industry. Where will we find continued funding for health benefits plans that deliver the health care that plan members will need in the most dire of circumstances? Some of our industry’s most recent decisions—the emergence of drug plan maximums (“caps”), for instance—are the opposite of hard decisions. A drug cap is the easy thing to do with respect to impacting the fewest plan members, but it means sacrificing the one percenters, the sickest of our sick, before taking a critical look at other spend that does not sustain or save lives. Whatever happened to insurance?
GSC will do its part to make it easier for advisors and plan sponsors to avoid such decisions in the future— through strategic positioning of biosimilars in drug plans; through the long-term goal of helping plan members better their health through coaching and an online portal that
rewards their best efforts; and through introducing highquality, virtual and community-based cognitive behavioural therapy to provide physicians with a sound alternative to the seemingly automatic antidepressant prescription.
And by the way, we’re working on other cool stuff too…
Well, if that was a meal, it was a bit of a slog—we admit it was not the tastiest—more like the written equivalent of an undressed kale salad.
To view the full PDF copy of this Edition, please click here